Jounce Therapeutics — Investor Presentation (January 2018)
25 slides from Jounce Therapeutics's investor presentation, Jan 8, 2018
Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Slide 2: Legal Disclaimer
Legal Disclaimer Various statements in this release concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding operating expenses, collaboration revenue and other financial results, the timing, progress and results of research and deve
Slide 3: Jounce Therapeutics
Jounce Therapeutics Develop and commercialize Discover first-in-class immunotherapies Predictive biomarkers Tumor immune composition 3 | Jounce Therapeutics © January, 2018 Developing first-in-class cancer immunotherapies to match the right therapy to the right patients
Slide 4: Jounce Investment Highlights
Jounce Investment Highlights • Engine to drive sustained discovery • New targets & biomarkers linked to tumor immune composition Robust Translational Science Platform Lead Candidate JTX-2011 Phase 2 Diverse, Broad Pipeline Significant Strategic Collaboration Experienced Founder & Management Team • P
Slide 5: 2017 Key Accomplishments
2017 Key Accomplishments 5 | Jounce Therapeutics © January, 2018 Upsized IPO, raising >$117m in gross proceeds Established new corporate headquarters Built discovery team to support Celgene collaboration and broader vision Presentation and posters at AACR, ASCO and SITC JTX-2011 ICONIC mon
Slide 6: 2018 Value Drivers
2018 Value Drivers JTX-2011 preliminary clinical efficacy results in Q2 Tumor types that have completed enrollment with biomarker and safety update IND for JTX-4014 (anti-PD-1) Initiate new JTX-2011 combination Next development candidate into IND enabling activities Continued investment in our trans
Slide 7: Immunotherapy Opportunities Beyond PD-1 Inhibitors
Immunotherapy Opportunities Beyond PD-1 Inhibitors 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% NSCLC, 1st line Melanoma, 1st line MSI-H, 2nd line+ Melanoma, 2nd line+ Bladder, 1st line Renal, 2nd line+ Bladder, 2nd line+ NSCLC, 2nd line+ HNSCC, 1st line+ Liver, 2nd line+ Gastric, 3rd line+ ORR for F
Slide 8: Immunotherapy Opportunities Beyond PD-1 Inhibitors: Translational Science Platform
Immunotherapy opportunities beyond PD-1 inhibitors T cells T cells + macrophages Macrophages No T cells or macrophages Hot / Cold Tumors • PD-1 inhibitor amenable • Opportunity to maximize benefit • High unmet medical need • Opportunity to expand the promise of immunotherapy Translational Science Pl
Slide 9: JTX-2011 Shifts Balance of T Cells Towards Anti-Tumor Activity
JTX-2011 Shifts Balance of T Cells Towards Anti-Tumor Activity APC “Primed” T effector cell ICOS↑ TCR 1st signal ICOS JTX-2011 ↑ IFN-γ↑ ↑ IFN-γ↑ Activation of T effector cells T regulatory cell NK cell X Selective reduction of intratumoral T regulatory cells “Non-Primed” T effector cell TCR ICOS 9 |
Slide 10: Critical Pre-clinical Requirements for In Vivo Efficacy
Critical Pre-clinical Requirements for In Vivo Efficacy Single Agent TS ICOS 3+ 0 1 0 2 0 3 0 4 0 0 2 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0 1 2 0 0 1 4 0 0 0 1 0 2 0 3 0 4 0 0 2 0 0 4 0 0 6 0 0 8 0 0 1 0 0 1 2 0 0 1 4 0 0 Days post-inoculation of SA1/N tumor cells T u m o r v o lu m e ( m m 3 ) Control Anti
Slide 11: ICONIC: Adaptive, Biomarker-Driven Clinical Study
ICONIC: Adaptive, Biomarker-Driven Clinical Study Phase 1 Dose Escalation, Safety, PK and PD Single Agent Dose Escalation Safety, PK/PD read-out at ASCO 2017* A All-comers, no biomarker enrichment Combo with nivolumab Dose EscalationB PK/PD Expansions PK/PD Expansions Phase 1 Safety, PK and PD Phase
Slide 12: Phase 1 Established Safety and RP2D
Phase 1 Established Safety and RP2D Phase 1 Data Presented at ASCO 2017 Phase 2 dose selection based on science and safety • Phase 1 patients heavily pre-treated, with median 4 prior therapies • Single agent dose range 0.003 mg/kg to 1 mg/kg, combo dose range 0.01 to 0.3 • PK / PD model created base
Slide 13: Phase 2 Indication Selection & Patient Enrichment via Biomarkers
Phase 2 Indication Selection & Patient Enrichment via Biomarkers ICOS Immunohistochemistry (IHC) Re na l Br ea st Bl ad de r Ov ar ian Pr os tat e St om ac h Co lon Me lan om a TN BC Lu ng HN SC C 0 50 100 % T um or s 3+ 2+ 1+ None ICOS protein levels vary across indications None (0) Low (1+) Medium
Slide 14: ICONIC: Phase 2 in Select Indications
ICONIC: Adaptive, Biomarker-Driven Clinical Study Phase 2 in Select Indications Phase 1 Safety, PK and PD Phase 2 Triggered Upon: Identification of safe dose where PK/PD predicts anticipated clinically effective dose Any solid tumor type HNSCC NSCLC New indications based on emerging science NSCLC HN
Slide 15: ICOS May Be an Ideal Target for Combination Therapy
ICOS May Be an Ideal Target for Combination Therapy APC “Primed” T effector cell ICOS↑ TCR 1st signal ICOS Potential Combination Advantages of the ICOS Mechanism CTLA-4 inhibitors PD-1 inhibitors Vaccines Radiation OX-40 agonists ICOS ICOS ICOS ↑ ↑ ↑ • Variety of agents induce ICOS in T cells • Indu
Slide 16: JTX-4014: Anti-PD-1 Program, IND in 2018
JTX-4014: Anti-PD-1 Program, IND in 2018 JTX-4014 Product Profile • Fully human IgG4 (hinge-stabilized) anti-PD-1 blocking antibody • Selectively recognizes human, cynomolgus and mouse PD-1, and not closely related family members • Blocks PD-1 binding to PD-L1 and PD-L2 across species • JTX-4014 clo
Slide 17: Translational Platform Expanding the Promise of Immunotherapy
Translational Platform Expanding the Promise of Immunotherapy Immunosuppressive macrophage-rich tumors Immune cell- lacking tumors Effector T cells M2-like suppressive macrophages Inflamed immune environment: Susceptible to PD-1 inhibitors Convert M2 mΦ to M1 Alter TME and recruit immune cells 17 |
Slide 18: Proof of Biology of New Immunosuppressive Macrophage Targets In Vivo
Proof of Biology of New Immunosuppressive Macrophage Targets In Vivo (Using Genetically Engineered KO Mice) MC38 tumor growth in normal mice MC38 tumor growth in mice lacking target 0 1 0 2 0 3 0 0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0 3 0 0 0 3 5 0 0 W T M C 3 8 D a y T u m o r V o lu m e ( m m 3 )
Slide 19: Jounce Antibodies Convert Macrophages to Anti-Tumor Phenotype
Jounce Antibodies Convert Macrophages to Anti-Tumor Phenotype • TNFa • IL-1b • CCL2 • IL-10 Pro-Inflammatory Anti-Inflammatory Jounce antibodies promote M1-like activation Jounce antibodies attenuate M2-like activation 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1 1 1 0 0 5 1 0 1 5 2 0 2 5 A n tib o d y c o n c e
Slide 20: Jounce Immunotherapy Pipeline
Jounce Immunotherapy Pipeline Program Target ID Discovery Pre-clinical Clinical Development JTX-2011 (ICOS) Multiple Solid Tumor Indications JTX-4014 (PD-1) Lead Macrophage Program Myeloid Enriched Solid Tumors Macrophage Targeting Multiple (Undisclosed) T Reg Multiple (Undisclosed) B Cells Multiple
Slide 21: Jounce and Celgene Strategic Collaboration
Jounce and Celgene Strategic Collaboration Co-develop and Co-commercialize Innovative Immunotherapies Collaboration Highlights • Global strategic collaboration, enabling comprehensive clinical strategy • Option based deal, preset opt-in fees and profit share, cost sharing after opt-in • Jounce retai
Slide 22: Financial Strength and Flexibility
Financial Strength and Flexibility Event Date Gross $ Comment Series A 2013 $47M Third Rock Ventures Series B 2015 $56M Fidelity, Wellington, others CELG Collaboration 2016 $225M upfront $36M equity US profit sharing on optioned programs Initial Public Offering 2017 $117M (gross) Upsized deal • NASD
Slide 23: Board of Directors and Leadership Team
Perry Karsen Chairman Cary Pfeffer, M.D. Director Robert Tepper, M.D. Director Robert Kamen, Ph.D. Director Duncan Higgons Director Barbara Duncan Director Luis A. Diaz, Jr., M.D. Director Richard Murray, Ph.D. Director Leadership Team Highly Experienced in Oncology and Immunotherapy Executive Team
Slide 24: 2018 Value Drivers
2018 Value Drivers JTX-2011 preliminary clinical efficacy results in Q2 Tumor types that have completed enrollment with biomarker and safety update IND for JTX-4014 (anti-PD-1) Initiate new JTX-2011 combination Next development candidate into IND enabling activities Continued investment in our trans
Slide 25: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Jounce Therapeutics — Investor Presentation (January 2018) on 6ix